Ligand-binding assays: Risk of using a platform supported by a single vendor

Bioanalysis

Volumn 1, Issue 3, 2009, Pages 629-636

  Yohrling, Jennifer ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; LIGAND;

ARTICLE; COMMERCIAL PHENOMENA; ECONOMICS; ELECTROCHEMISTRY; FLUOROMETRY; GENETIC PROCEDURES; HUMAN; IMMUNOASSAY; INSTRUMENTATION; LUMINESCENCE; MACROMOLECULE; METHODOLOGY; PHARMACOKINETICS; REPRODUCIBILITY;

BIOLOGICAL MARKERS; BIOSENSING TECHNIQUES; COMMERCE; ELECTROCHEMISTRY; FLUOROMETRY; HUMANS; IMMUNOASSAY; INDICATORS AND REAGENTS; LIGANDS; LUMINESCENCE; MACROMOLECULAR SUBSTANCES; PHARMACOKINETICS; REPRODUCIBILITY OF RESULTS;

EID: 78149501036     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.09.46     Document Type: Review

References (31)

1. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry 8, 871-874 (1971).
2. Van Weemen BK, Schuurs AH. Immunoassay using antigen-enzyme conjugates. FEBS Lett. 15, 232-236 (1971).
3. Seitz WR. Immunoassay labels based on chemiluminescence and bioluminescence. Clin. Biochem. 17, 120-125 (1984).
4. Hemmilä I. Fluoroimmunoassays and immunofuorometric assays. Clin. Chem. 31, 359-370 (1985).
5. Rieutord A, Prognon P, Brion F, Mahuzier G. Liquid chromatographic determination using lanthanides as time-resolved luminescence probes for drugs and xenobiotics: advantages and limitations. Analyst 122, 59R-66R (1997).
6. Gudgin Dicson EF, Pollak A, Diamandis EP Time-resolved detection of lanthanide luminescence for ultrasensitive bioanalytical assays. J. Photochem. Photobiol. B. Biol. 27, 3-19 (1995).
7. Butcher H, Kennette W, Collins O, Demoor J, Koropatnick J. A sensitive time-resolved fuorescent immunoassay for metallothionein protein. J. Immunol. Methods 272, 247-256 (2003).
8. Ullman EF, Kirakossian H, Singh S et al. Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. Proc. Natl Acad. Sci. USA 91, 5426-5430 (1994).
9. McGiven JA, Sawyer J, Perrett LL et al. A new homogeneous assay for high throughput serological diagnosis of brucellosis in ruminants. J. Immunol. Methods 337, 7-15 (2008).
10. Blackburn, GF, Shah, HP, Kenten, JH et al. Electrochemiluminescence detection for development of immunoassays and DNA probe assays for clinical diagnostics. Clin. Chem. 37, 1534-1539 (1991).
11. Liang M, Klakamp SL, Funelas C et al. Detection of high-and low-affnity antibodies against a human monoclonal antibody using various technology platform. Assay Drug Dev. Technol. 5, 655-662 (2007).
12. Guglielmo-Viret V, Attrée O, Blanco-Gros V, Thullier P. Comparison of electrochemiluminescence assay and ELISA for the detection of Clostridium botulinum type B neurotoxin. J. Immunol. Methods 301, 164-172 (2005).
13. A Guide to Developing ORIGIN Assays on the M-Series Analyzers. IGEN International, Inc., MD, USA (2003).
14. Abdiche Y, Malashock D, Pinkerton A, Pons J. Determining kinetics and affnities of protein interactions using a parallel real-time label-free biosensor. Octet. Anal. Biochem. 377, 209-217 (2008).
15. Mytych DT, La S, Barger T, Ferbas J, Swanson SJ. The development and validation of a sensitive, dual-fow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin a and epoetin a in human serum. J. Pharm. Biomed. Anal. 49, 415-526 (2009).
16. Vaisocherová H, Faca VM, Taylor HP, Hanash S, Jiang S. Comparative study of SPR and ELISA methods based on ana lysis of CD166/ALCAM levels in cancer and control human sera. Biosens. Bioelectron. 24(7), 2143-2148 (2009).
17. Lofgren JA, Dhandapani S, Pennucci JJ et al. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J. Immunol. 178, 7467-7472 (2007).
18. Katsamba PS, Navritalova I, Calderon-Cacia M et al. Kinetic ana lysis of a high-affnity antibody/antigen interaction performed by multiple Biacore users. Anal. Biochem. 352, 208-221 (2006).
19. Abdiche YN, Malashock DS, Pinkerton A, Pons J. Exploring blocking assays using Octet, ProteOn, and Biacore biosensors. Anal. Biochem. 386(2), 172-180 (2009).
20. Ray CA, Bowsher RR, Smith WC et al. Development, validation and implementation of a multiplex immunoassay for the simultaneous determination of fve cytokines in human serum. J. Pharm. Biomed. Anal. 36, 1037-1044 (2005).
21. Toedter G, Hayden K, Wagner C, Brodmerkel C. Simultaneous detection of eight analytes in human serum by two commercially available platforms for multiplex cytokine analysis. Clin. Vaccine Immunol. 15, 42-48 (2008).
22. Backen AC, Cummings J, Mitchell C, Jayson G, Ward TH, Dive C. 'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. J. Immunol. Methods 342, 106-114 (2009).
23. Kahn SS, Smith MS, Reda D et al. Multiplex bead array assays for detection of soluble cytokines. Comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin. Cytom. 61B, 35-39 (2004).
24. Lash GE, Scaife PJ, Innes BA et al. Comparison of three multiplex cytokine ana lysis systems: Luminex, SearchLight™ and FAST Quant®. J. Immunol. Methods 309, 205-208 (2006).
25. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20, 1885-1900 (2003).
26. Lee JW, Devanarayan V, Barrett YC et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23, 312-328 (2006).
27. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48, 1267-1281 (2008).
28. Covello VT. Decision ana lysis and risk management decision making: issues and methods. Risk Anal. 7, 131-139 (1987).
29. Klinke A, Renn O. A new approach to risk evaluation and management: risk-based, precaution-based, and discourse-based strategies. Risk Anal. 22, 1071-1094 (2002).
30. Hammond O, Reynolds J, Rubinstein LJ, Sikkema D, Marchese RD. Complexities of clinical assay development and optimization prior to frst-in-man immunization trials-a description of immunogenicity assay development for the testing of samples from a Phase I Alzheimer's vaccine trial. J. Immunoassay Immunochem. 29, 332-347 (2008).
31. Joelsson D, Moravec P, Troutman M, Pigeon J, DePhillips P. Optimizing ELISAs for precision and robustness using laboratory automation and statistical design of experiments. J. Immunol. Methods 20, 35-41 (2008).